Cardiology Today Current Issue

The following articles appeared in the print edition of Cardiology Today.

Table of Contents

• Catheter ablation for AF: Debate continues over benefit
• Drug labels, QT prolongation and ECG recommendations David Woosley, MPH; Klaus Romero, MS, MD; Jared Tate, PharmD; Tyler Gallo, PharmD; C. Will Heise, MD; Raymond L. Woosley, MD, PhD; R. David Woosley, MPH
• FDA approves baroreflex activation therapy for advanced HF
• FDA grants fast track designation to dapagliflozin for worsening heart failure
• AHA: Prescription fish oil effectively lowers high triglycerides
• Aspirin, rivaroxaban similar for recurrent stroke prevention in certain patients
• Focus on modifiable risk factors paramount for CVD prevention in childhood cancer survivors
• Healthy plant-based diet lowers risk for CVD mortality, morbidity
• High-intensity statin therapy confers improved outcomes in older patients with ACS
• Complete revascularization superior to culprit lesion-only PCI for STEMI, multivessel CAD: COMPLETE
• DAPA-HF: Dapagliflozin offers new approach to treatment of HFrEF, even without diabetes
• ENTRUST-AF PCI: Dual therapy with edoxaban noninferior to triple therapy in AF, PCI
• Indicators in gut microbiome may lead to better diagnosis, treatment of high BP
• ISAR-REACT 5: Prasugrel superior to ticagrelor in patients with ACS, planned invasive evaluation
• PARAGON-HF: Sacubitril/valsartan misses primary endpoint for HFpEF; may still provide insight into unmet need
• POPular Genetics: Genotyping strategy for P2Y12 inhibitor selection after PCI yields less bleeding risk
• THEMIS: Ticagrelor-aspirin DAPT may benefit selected patients with diabetes, stable CAD
• COMPLETE
• DAPA-HF
• DEFINE-HF
• ENTRUST-AF PCI
• ISAR-REACT 5
• ORION-11
• PARAGON-HF
• THEMIS